Cupid invests in GII Healthcare Investment

GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo

Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally

Sun Pharma settles patent litigation with Incyte

Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’

Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease

Evonik opens new medical device center in Shanghai

The company’s largest center for medical device applications, serving the entire Asian market

Panacea Biotec reaches settlement with Apotex

Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension

Hexaware and Abluva join forces to deliver secure Agentic AI solutions for life sciences industry

This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security

Senores Pharmaceuticals to increase stake in Havix

Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations

DKSH and Bayer partner across multiple markets in Southeast Asia